Sangamo Therapeutics, Inc.
(NASDAQ : SGMO)

( )
SGMO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.47%244.391.5%$899.91m
MRNAModerna, Inc. -0.87%148.650.0%$810.71m
VRTXVertex Pharmaceuticals, Inc. 0.02%287.371.9%$506.97m
GILDGilead Sciences, Inc. 0.42%62.621.0%$488.11m
REGNRegeneron Pharmaceuticals, Inc. 0.00%595.402.6%$457.36m
NVAXNovavax, Inc. -0.49%56.8775.7%$415.43m
ILMNIllumina, Inc. -0.40%190.273.3%$360.10m
SNSSSunesis Pharmaceuticals, Inc. 0.00%3.670.7%$256.55m
BIIBBiogen, Inc. 0.07%210.771.8%$247.60m
BNTXBioNTech SE -1.37%155.350.0%$205.84m
CRSPCRISPR Therapeutics AG -1.32%62.950.6%$170.70m
BMRNBioMarin Pharmaceutical, Inc. 0.00%84.984.2%$117.72m
AXSMAxsome Therapeutics, Inc. -0.84%40.301.8%$98.98m
EXASEXACT Sciences Corp. -0.92%40.7517.7%$94.75m
TECHBio-Techne Corp. 0.00%353.184.5%$94.16m

Company Profile

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.